Advance Nanotech Continues to Grow Senior Management Team; Nanotechnology Leader Appoints Dr. Fred Allen To Head Materials Group.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- Advance Nanotech, Inc., (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB:AVNA AVNA Atrioventricular Node Artery .OB), the premier provider of financing and support services support services Psychology Non-health care-related ancillary services–eg, transportation, financial aid, support groups, homemaker services, respite services, and other services to drive the commercialization of nanotechnology discoveries, today announced the appointment of Dr. Fred Allen For the New Zealand rugby union player and coach, see . Fred Allen (born John Florence Sullivan on May 31 1894 in Cambridge, Massachusetts, died March 17 1956 in New York City) was an American comedian whose absurdist, pointed radio show (1934–1949) made him one to the position of Senior Vice President, Materials. Dr. Allen will be responsible for managing all of the firm's partnerships and investments related to materials sciences. He will report directly to Advance Nanotech CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Magnus Gittins. "Dr. Allen possesses a strong background in research and development in nanotechnology and materials science. His experiences in coordinating research and development initiatives with sales, marketing, IP management, safety, manufacturing and external regulator efforts will prove invaluable in his new role at Advance Nanotech," said Gittins. "We are very pleased to have him join the Advance team." Prior to joining Advance Nanotech, Dr. Allen held a management position in R&D at Engelhard Corporation where he led the technology assessment function and nanotechnology program. Dr. Allen also supported Engelhard's Ventures Group, where he played a key role in evaluating commercial opportunities for the firm. He is a co-founder of the Greater Garden State Nanotechnology Alliance. Dr. Allen's materials expertise spans minerals, ceramics and metals and involves crystal structure determination using X-ray and electron diffraction Electron diffraction The phenomenon associated with interference processes that occur when electrons are scattered by atoms to form diffraction patterns. , optical and electron microscopy electron microscopy Technique that allows examination of samples too small to be seen with a light microscope. Electron beams have much smaller wavelengths than visible light and hence higher resolving power. , image analysis, electron microprobe The electron microprobe is an analytical tool used to non-destructively determine the chemical composition of small volumes of solid materials. It uses a high-energy focused beam of electrons to generate X-rays characteristic of the elements present within a sample volumes 1 to 3 analysis, surface chemical analysis, and thermal analysis Thermal analysis is a branch of materials science where the properties of materials are studied as they change with temperature. Techniques include:
Harvard College, originally for men, was founded in 1636 with a grant from the General Court of the Massachusetts Bay Colony. and The State University of New York (body) State University of New York - (SUNY) The public university system of New York State, USA, with campuses throughout the state. at Stony Brook. He is responsible for ten patent filings and 30 publications and presentations throughout his career. Advance Nanotech is currently funding 18 portfolio companies in the electronics, biopharma, and materials industries. The firm provides services ranging from funding, to human capital and research equipment essential to ensuring that the most promising companies can accelerate the path to rapid commercialization. In this way, investor exposure to any particular technology is mitigated with Advance Nanotech retaining the option to increase investment in those technologies that successfully mature. Dr. Allen will be responsible for overseeing the firm's materials-focused investments. About Advance Nanotech, Inc. Advance Nanotech Inc. is dedicated to ensuring nanotechnology discoveries reach maximum market potential through successful commercialization. Advance is the trusted guide to commercial success for nanotech entrepreneurs spanning the globe, partnering with leading universities to provide scientists and researchers with mission critical infrastructure support to transform their discoveries to marketable solutions. The organization provides a range of services and support including financing, leadership assets and counsel on intellectual property, licensing and regulatory issues. With a portfolio of nearly 20 companies developing technologies which offer potentially breakthrough nanotechnology discoveries in the electronics, biopharma and materials sectors, Advance's goal is to transform the potential for nanotechnology discoveries into innovative products that further evolve existing industries and enable new markets. This document contains forward-looking statements by Advance Nanotech regarding its expectations as to its business, and involves risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those addressed in the forward-looking statements. Factors that may cause such a difference include, but are not limited to, problems and risks associated with developments in the nanotechnology industry in general and in Advance Nanotech's products under development in particular; the potential failure of Advance Nanotech's products under development to prove safe and effective in application; uncertainties inherent in the early stage of Advance Nanotech's products under development; failure to successfully implement or complete research programmes; failure to receive marketing clearance from regulatory agencies for our products under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Advance Nanotech's business, structure or projections; the development of competing products; uncertainties related to Advance Nanotech's dependence on third parties and partners; and those risks described Advance Nanotech 's filings with the SEC. Advance Nanotech disclaims any obligation to update these forward-looking statements. Further information about these and other relevant risks and uncertainties may be found in the Advance Nanotech's findings with the Securities and Exchange Commission, all of which are available from the Commission as well as other sources. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion